These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 36152876)

  • 1. Suvorexant maintenance enhances the reinforcing but not subjective and physiological effects of intravenous cocaine in humans.
    Stoops WW; Strickland JC; Hatton KW; Hays LR; Rayapati AO; Lile JA; Rush CR
    Pharmacol Biochem Behav; 2022 Oct; 220():173466. PubMed ID: 36152876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine.
    Gentile TA; Simmons SJ; Barker DJ; Shaw JK; España RA; Muschamp JW
    Addict Biol; 2018 Jan; 23(1):247-255. PubMed ID: 28419646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine.
    Gentile TA; Simmons SJ; Watson MN; Connelly KL; Brailoiu E; Zhang Y; Muschamp JW
    Neuropsychopharmacology; 2018 Apr; 43(5):1001-1009. PubMed ID: 28741623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of hypocretin/orexin receptor blockade on drug-taking and ultrasonic vocalizations (USVs) associated with low-effort self-administration of cathinone-derived 3,4-methylenedioxypyrovalerone (MDPV) in rats.
    Simmons SJ; Martorana R; Philogene-Khalid H; Tran FH; Gentile TA; Xu X; Su S; Rawls SM; Muschamp JW
    Psychopharmacology (Berl); 2017 Nov; 234(21):3207-3215. PubMed ID: 28786030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.
    Born S; Gauvin DV; Mukherjee S; Briscoe R
    Regul Toxicol Pharmacol; 2017 Jun; 86():181-192. PubMed ID: 28279667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual orexin receptor antagonist drug suvorexant can help in amelioration of predictable chronic mild stress-induced hyperalgesia.
    Chavan P; Chikahisa S; Shiuchi T; Shimizu N; Dalanon J; Okura K; Séi H; Matsuka Y
    Brain Res Bull; 2022 Oct; 188():39-46. PubMed ID: 35868501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cocaine abuse and midbrain circuits: Functional anatomy of hypocretin/orexin transmission and therapeutic prospect.
    Simmons SJ; Gentile TA
    Brain Res; 2020 Mar; 1731():146164. PubMed ID: 30796894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary examination of the orexin system on relapse-related factors in cocaine use disorder.
    Suchting R; Yoon JH; Miguel GGS; Green CE; Weaver MF; Vincent JN; Fries GR; Schmitz JM; Lane SD
    Brain Res; 2020 Mar; 1731():146359. PubMed ID: 31374218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-selective orexin-receptor antagonist attenuates stress-re-stress-induced core PTSD-like symptoms in rats: Behavioural and neurochemical analyses.
    Prajapati SK; Krishnamurthy S
    Behav Brain Res; 2021 Feb; 399():113015. PubMed ID: 33212086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of drug purchase tasks in medications development research: orexin system regulation of cocaine and drug demand.
    Strickland JC; Hatton KW; Hays LR; Rayapati AO; Lile JA; Rush CR; Stoops WW
    Behav Pharmacol; 2023 Aug; 34(5):275-286. PubMed ID: 37403694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual orexin receptor blocker suvorexant attenuates hypercapnic ventilatory augmentation in mice.
    Fukushi I; Yokota S; Takeda K; Terada J; Umeda A; Yoshizawa M; Kono Y; Hasebe Y; Onimaru H; Pokorski M; Okada Y
    Brain Res; 2022 Nov; 1795():148061. PubMed ID: 36037880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
    Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects.
    Sun H; Yee KL; Gill S; Liu W; Li X; Panebianco D; Mangin E; Morrison D; McCrea J; Wagner JA; Troyer MD
    J Psychopharmacol; 2015 Nov; 29(11):1159-69. PubMed ID: 26464455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of suvorexant.
    Stahl SM
    CNS Spectr; 2016 Jun; 21(3):215-8. PubMed ID: 27322687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice.
    Kaushik MK; Aritake K; Cherasse Y; Imanishi A; Kanbayashi T; Urade Y; Yanagisawa M
    Sleep; 2021 Aug; 44(8):. PubMed ID: 33609365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orexin-mediated restoration of hippocampal synaptic potentiation in mice with established cocaine-conditioned place preference.
    Lu GL; Lee MT; Chiou LC
    Addict Biol; 2019 Nov; 24(6):1153-1166. PubMed ID: 30276922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suvorexant: first global approval.
    Yang LP
    Drugs; 2014 Oct; 74(15):1817-22. PubMed ID: 25227290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
    Schoedel KA; Sun H; Sellers EM; Faulknor J; Levy-Cooperman N; Li X; Kennedy WP; Cha JH; Lewis NM; Liu W; Bondiskey P; McCrea JB; Panebianco DL; Troyer MD; Wagner JA
    J Clin Psychopharmacol; 2016 Aug; 36(4):314-23. PubMed ID: 27253658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of the dual orexin receptor antagonist suvorexant to engender drug discrimination in rats.
    Steiner MA; Toeroek-Schafroth M; Dacome L; Tessari M
    J Psychopharmacol; 2023 Dec; 37(12):1261-1264. PubMed ID: 37982383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.